SAVE THE DATE!
July 8-9, 2024 | The Westin Jersey City Newport
The premiere event developed by, and dedicated to communicators in Life Sciences...
As an event developed by industry leaders, the Pharma PR & Communications Summit delivers the chance to hear from top organizations on conquering new strategies, demonstrating value to the press and public, and pushing boundaries with innovative approaches to outreach. On a personal level, we'll also provide key opportunities to learn from and expand upon your network to ensure you stay relevant at your current company or wherever your career may take you. This is a must-attend event for anyone working in the life science communications industry.
Top Reasons to Attend the Fierce Pharma PR & Communications Summit
An Event Tailored for You
Stay Ahead of Current Trends
Diverse Speaking Staff
Great Conference Program
Networking Opportunities
Who Should Attend?
Life science marketing professionals from pharmaceutical, biotechnology and medical device companies, as well as agencies responsible for:
-
Communications: Corporate, Brand, Internal, External, Integrated, Multichannel
-
Public /Media Relations
-
Investor Relations
-
Diversity, Equity and Inclusion
-
Employee Engagement
-
Social Media
-
Public/Government Affairs
-
Advocacy, and Patient Relations
-
Community/Advocacy Relations
-
Marketing
-
Public Policy
Maximize learning by attending as a group and save 25% or more.
If you plan to send multiple people from your team to the Fierce Pharma PR & Communications Summit, please contact us for custom group pricing.
The 2023 Summit Welcomed Over 220 Senior Communications Executives from Top Pharmaceutical and Biotech Companies. See What Companies Attended:
- 21 Grams
- Abbvie
- Agenus
- AHA Creative Strategies
- Aldevron
- Allergan Aesthetics
- Alnylam Pharmaceuticals
- Amgen
- Arcturus Therapeutics
- Astellas
- AstraZeneca
- BeiGene
- BioAgilytix
- Blueprint Medicines
- Braeburn
- Bristol Myers Squibb
- Calcium + Company
- Cision
- Clyde Group
- Consumer Technology Association
- CSL
- Cullinan Oncology
- Daiichi Sankyo
- Edocate Ltd.
- Eikon Therapeutics
- EMD Serono Inc.
- Encoded Therapeutics
- FINN Partners
- Flagship Pioneering
- Forge Biologics
- FTI Consulting
- Fullintel
- GCI Health
- GE HealthCare
- Genmab
- Genmab
- Gilead Sciences
- Golin
- GSK
- Havas Red
- Horizon Therapeutics
- ICR Westwicke
- Insider Inc.
- Insmed
- Insocius
- Jaguar Health
- Kallyope
- Kallyope
- Kinnate Biopharma
- LEO Pharma
- LifeScan
- Lippe Taylor
- Lundbeck
- Makovsky
- Massachusetts Biotechnology Council
- Merck
- Merus
- Metagenomi
- MMC
- MorphoSys
- Multiplier AI
- National Organization for Rare Disorders
- Novo Nordisk
- Novocure
- Ocelot Bio
- Ocugen
- Optimal
- Orangefiery
- Organon
- PacBio
- Padilla
- Passage Bio
- Pfizer
- Phathom Pharmaceuticals
- Pioneering Collective
- PTC Therapeutics
- Real Chemistry
- Red Havas
- Regeneron Pharmaceutical
- Sam Brown Inc. Healthcare Communications
- SCYNEXIS
- Slate360
- SPI Group
- Sumitomo Pharma America
- Takeda
- The 180 Group
- UCB
- Urovant Sciences
- Viatris
- Vor Bio
- Waterhouse Brands
- Waters Corporation
- WE Communications
- Weber Shandwick
- WPP
- Zymeworks